These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32169390)

  • 21. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
    Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
    Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women.
    Fischer P; Pawlowski A; Cao D; Bell D; Kitson G; Darsley M; Johansson-Lindbom B
    Vaccine; 2021 Jul; 39(32):4489-4499. PubMed ID: 34215454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE).
    Simon JK; Staerke NB; Hemming-Harlo M; Layle S; Dagan R; Shekar T; Pedley A; Jumes P; Tamms G; Sterling T; Musey L; Buchwald UK;
    Vaccine; 2022 Feb; 40(9):1342-1351. PubMed ID: 35039194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial.
    Prymula R; Pazdiora P; Traskine M; Rüggeberg JU; Borys D
    Vaccine; 2014 May; 32(25):3025-34. PubMed ID: 24699466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neither antibody to a group B streptococcal conjugate vaccine nor the vaccine itself is teratogenic in rabbits.
    Paoletti LC; Guttormsen HK; Christian MS; Hoberman AM; McInnes P
    Hum Vaccin; 2008; 4(6):435-43. PubMed ID: 18443428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic review of the clinical development of group B streptococcus serotype-specific capsular polysaccharide-based vaccines.
    Dzanibe S; Madhi SA
    Expert Rev Vaccines; 2018 Jul; 17(7):635-651. PubMed ID: 29961350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults.
    Stacey HL; Rosen J; Peterson JT; Williams-Diaz A; Gakhar V; Sterling TM; Acosta CJ; Nolan KM; Li J; Pedley A; Benner P; Abeygunawardana C; Kosinski M; Smith WJ; Pujar H; Musey LK
    Hum Vaccin Immunother; 2019; 15(3):530-539. PubMed ID: 30648919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants.
    Madhi SA; Dangor Z; Heath PT; Schrag S; Izu A; Sobanjo-Ter Meulen A; Dull PM
    Vaccine; 2013 Aug; 31 Suppl 4():D52-7. PubMed ID: 23973347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants.
    Prymula R; Szenborn L; Silfverdal SA; Wysocki J; Albrecht P; Traskine M; Gardev A; Song Y; Borys D
    Vaccine; 2017 Aug; 35(35 Pt B):4603-4611. PubMed ID: 28729019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a multiplexed opsonophagocytic killing assay (MOPA) for group B Streptococcus.
    Choi MJ; Noh JY; Cheong HJ; Kim WJ; Lin SM; Zhi Y; Lim JH; Lim S; Seo HS; Song JY
    Hum Vaccin Immunother; 2018 Jan; 14(1):67-73. PubMed ID: 28933634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial.
    Turner M; Papadimitriou A; Winkle P; Segall N; Levin M; Doust M; Johnson C; Lucksinger G; Fierro C; Pickrell P; Raanan M; Tricou V; Borkowski A; Wallace D
    Hum Vaccin Immunother; 2020 Oct; 16(10):2456-2464. PubMed ID: 32119591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The immunogenicity and safety of Group B Streptococcal maternal vaccines: A systematic review.
    Bjerkhaug AU; Ramalingham S; Mboizi R; Le Doare K; Klingenberg C
    Vaccine; 2024 Jan; 42(2):84-98. PubMed ID: 38072754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune responses against group B
    Dhar N; Mohamed E; Kirstein F; Williams M; Dorasamy S; van Zyl P; Robertson MJ; Anderson T; Harden LM; Jardine K; Veeraraghavan B; Wilson S; Tippoo P; Madhi SA; Kwatra G
    iScience; 2023 Aug; 26(8):107380. PubMed ID: 37575182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opsonophagocytic Antibodies to Serotype Ia, Ib, and III Group B Streptococcus among Korean Infants and in Intravenous Immunoglobulin Products.
    Kim HW; Lee JH; Cho HK; Lee H; Seo HS; Lee S; Kim KH
    J Korean Med Sci; 2017 May; 32(5):737-743. PubMed ID: 28378545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization.
    Buurman ET; Timofeyeva Y; Gu J; Kim JH; Kodali S; Liu Y; Mininni T; Moghazeh S; Pavliakova D; Singer C; Singh S; Handke LD; Lotvin J; Prasad AK; Scully IL; Donald RGK; Jansen KU; Anderson AS
    J Infect Dis; 2019 Jun; 220(1):105-115. PubMed ID: 30778554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine.
    Baker CJ; Rench MA; McInnes P
    Vaccine; 2003 Jul; 21(24):3468-72. PubMed ID: 12850362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old.
    Palazzi DL; Rench MA; Edwards MS; Baker CJ
    J Infect Dis; 2004 Aug; 190(3):558-64. PubMed ID: 15243932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study.
    Leroux-Roels G; Maes C; De Boever F; Traskine M; Rüggeberg JU; Borys D
    Vaccine; 2014 Nov; 32(50):6838-46. PubMed ID: 24607003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.
    Rupp R; Hurley D; Grayson S; Li J; Nolan K; McFetridge RD; Hartzel J; Abeygunawardana C; Winters M; Pujar H; Benner P; Musey L
    Hum Vaccin Immunother; 2019; 15(3):549-559. PubMed ID: 30689507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.